Status:
UNKNOWN
Evaluation of Ultrasensitive Chromosomal Aneuploidy Detection for Detecting Minimal Residual Disease in Multiple Myeloma
Lead Sponsor:
Shanghai Changzheng Hospital
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Brief Summary
Despite the significantly higher complete remission rates and improved survival achieved over the last decade，multiple myeloma (MM) patients continue to relapse due to persistence of minimal residual ...
Detailed Description
In multiple myeloma, Minimal Residual Disease (MRD) refers to myeloma cells that are present in the bone marrow after a clinical response has been measured and the patient is in remission. A patient w...
Eligibility Criteria
Inclusion
- Patients new diagnosed with MM and with the curative effect at least VGPR.
- Male or female patients aged \>= 18 years.
- Participants signed informed consent form.
Exclusion
- Age under 18 years
- Individuals unwilling to sign the consent form or unwilling to provide PB for test or unwilling to provide the medical record.
- Individuals unwilling to participate in this trial.
Key Trial Info
Start Date :
October 20 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 20 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04122092
Start Date
October 20 2019
End Date
October 20 2022
Last Update
November 18 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Juan Du
Shanghai, China